Tranzyme Pharma is refocusing efforts on TZP-102, it’s diabetic gastroparesis drug treatment, after the failure of it’s flagship drug Ulimorelin.
Tranzyme Pharma & the FDA were not happy with the results of the Phase III trial results for Ulimorelin. Ulimorelin is similar to Tranzyme’s other drug TZP-102, in that it uses a ghrelin receptor agonist to stimulate motility in the gut. The drug was meant to treat people with delayed gastrointenstinal recovery / post operative ileus which is most often associated with gastrointestinal or gynecological surgery. Continue reading “Tranzyme Still Optimistic About Gastroparesis Drug Despite Stumbling Blocks” »
Tranzyme’s TZP-102 is a Ghrelin receptor agonist designed for treatment of Gastroparesis in diabetic patients. Phase IIb trials are currently underway to further test it’s efficacy.
Ghrelin is a hormone that is generated within the walls of the stomach. It’s mainly responsible for the feeling of hunger along with helping to gear up the digestive system for food intake. Leptin is another digestive hormone that is almost the opposite of Ghrelin in that it promotes feelings of satiety & lowers appetite. Those with Gastroparesis often have problems with loss of appetite & early feelings of fullness along with nausea & vomiting. While it’s known that usually a loss of digestive motility is the reason for these symptoms, it is not often known where the loss of motility came from. In some cases motility is not an issue, yet symptoms remain. It is possible that those suffering from Gastroparesis may be dealing with an underproduction of Ghrelin or an overproduction of Leptin. It is also possible that these hormone levels are fine but some other issue exists like nerve or muscle damage. Regardless of the cause, increasing production of Ghrelin may be beneficial to those dealing with Gastroparesis as it may allow the digestive system to regain some lost motility while improving appetite & reducing feelings of fullness. Continue reading “Tranzyme’s TZP-102 Gastroparesis Treatment Starts Phase IIb Trials” »